Welcome to LookChem.com Sign In | Join Free   Post buying lead  Chemical Tools
Post Buying Lead

Basic information

  • Name:

  • Mosapride citrate

  • CAS No.:

  • 112885-42-4

  • Formula:
  • C21H25ClFN3O3.C6H8O7
  • Synonyms:
  • Gasmotin;Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Benzamide,4-amino-5-chloro-2-ethoxy-N- [[4-[(4-fluorophenyl)methyl]-2-morpholinyl]- methyl]-,2-hydroxy-1,2,3-propanetricarboxylate (1:1);(+-)-4-Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide citrate;Gasmotin (TN);4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; 2-hydroxypropane-1,2,3-tricarboxylic acid;AS 4370;（±）- 4 –Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide citrate dihydrate;4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]-benzamide 2-hydroxy-1,2,3-propanetricarboxylate;

Related products

Other Products

Home > Hot Product_List > Mosapride Citrate
Supplier Location:
China (Mainland)(26)India(2)United States(1)
Business Type:
Importer/Exporter(22)Lab/Research institutions(3)Manufacturers(2)
Certificates:
Production License(2)ISO(1)

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Specification

The CAS register number of Mosapride Citrate is 112885-42-4. It also can be called as Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and the IUPAC name about this chemical is 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; 2-hydroxypropane-1,2,3-tricarboxylic acid. The molecular formula about this chemical is C27H33ClFN3O10 and the molecular weight is 614.02. It belongs to the Gastroprokinetic Agent.

Physical properties about Mosapride Citrate are: (1)ACD/LogP: 2.82; (2)ACD/LogD (pH 5.5): 1.98; (3)ACD/LogD (pH 7.4): 2.79; (4)ACD/BCF (pH 5.5): 11.7; (5)ACD/BCF (pH 7.4): 76.6; (6)ACD/KOC (pH 5.5): 116.16; (7)ACD/KOC (pH 7.4): 760.78; (8)#H bond acceptors: 6; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 8; (11)Polar Surface Area: 45.25Å2; (12)Flash Point: 286 °C; (13)Enthalpy of Vaporization: 82.9 kJ/mol; (14)Boiling Point: 549.2 °C at 760 mmHg; (15)Vapour Pressure: 4.11E-12 mmHg at 25°C.

The Mosapride Citrate is used for  functional dyspepsia with heartburn, belching, nausea, vomiting, early satiety, the abdominal distension, gastrointestinal symptoms such as upper abdominal pain. In addition, this chemical can also be used for gastroesophageal reflux disease, diabetic gastroparesis, and gastric resection in patients with dysfunction of the stomach.

You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)C(O)(CC(=O)O)CC(=O)O.Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3
(2)InChI: InChI=1/C21H25ClFN3O3.C6H8O7/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
(3)InChIKey: HUZTYZBFZKRPFG-UHFFFAOYAN
(4)Std. InChI: InChI=1S/C21H25ClFN3O3.C6H8O7/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
(5)Std. InChIKey: HUZTYZBFZKRPFG-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 400mg/kg (400mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.
mouse LD50 intraperitoneal 914mg/kg (914mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.
mouse LD50 oral > 3gm/kg (3000mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.
mouse LD50 subcutaneous > 1gm/kg (1000mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.
rat LD50 intraperitoneal > 1gm/kg (1000mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LIVER: OTHER CHANGES		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.
rat LD50 oral > 3gm/kg (3000mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.
rat LD50 subcutaneous > 1gm/kg (1000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993.

 

©2008 LookChem.com,License:ICP NO.：Zhejiang10014259

[Hangzhou]86-571-85317600,85317603,85317620